Smart Insulin Pens Enter the Electric Era: Kailian Medical Unveils Next-Gen Intelligent Insulin Delivery Solution for Precision Diabetes Management

Diabetes management has entered an era of precision management based on digital and intelligent devices.

In clinical practice, multiple diabetes diagnosis and treatment guidelines issued by authoritative associations and institutions indicate that diabetes management should not adopt a “one-size-fits-all” approach. Instead, personalized management should be implemented for different populations and diabetes subtypes, with the recommended use of digital and intelligent devices—such as continuous glucose monitoring (CGM) systems, smart insulin pens, and insulin pumps—to enable refined management.

Against this backdrop, continuous glucose monitoring (CGM) devices, as a category of monitoring equipment, were the first to witness the wave of domestic substitution. With the continuous entry of Chinese enterprises and the steady improvement of their R&D capabilities, the sector has gradually shifted from domestic substitution to indigenous innovation. Meanwhile, insulin delivery devices, including insulin pens and insulin pumps, are also seeing the rise of domestic innovative forces, with several products featuring digital intelligence successively launched onto the market.

As products continue to evolve and innovate, one cannot help but wonder: How far have we come? Have we truly achieved refined, digital-intelligent management of diabetes?

The answer to this question may be that we have achieved phased results, but there is still a certain distance from the ultimate goal.

CGM has addressed the first challenge of refined diabetes management—continuous glucose monitoring. As previously noted, with an increasing number of market entrants and their continued in-depth engagement, core technologies have achieved breakthroughs while product accessibility has further improved. This indicates that, at least in the monitoring phase, the industry has laid a relatively solid foundation for refined diabetes management.

As for injection devices, insulin pumps are highly regarded by the industry due to their features such as precise infusion and micro-adjustment. However, owing to their high cost and patients’ relatively low level of awareness, the market penetration of insulin pumps continues to face challenges related to R&D, costs, and patient education. Consequently, some media outlets have pointed out that among diabetic patients currently undergoing insulin therapy, 70% still choose to use insulin pens for administration.

However, two major characteristics of traditional mechanical insulin pens limit their application in the refined management of diabetes: First, the insulin delivery settings lack precision; issues such as omitted priming, premature needle removal leading to insufficient fluid or leakage, consequently compromise dose accuracy. Second, they lack data recording and storage capabilities, thereby precluding injection reminders and visualized analysis of the correlation between dosage and therapeutic effects.

Although several approved smart insulin pens have emerged on the market, their infusion accuracy still needs improvement, or they only offer basic data recording and storage functions, with reminder and data analysis features yet to be perfected. In other words,The refined, digital-intelligent management ecosystem for diabetes, built upon smart insulin pens, has taken initial shape but still requires further improvement.

To further elaborate, achieving refined, data-driven intelligent management of diabetes based on smart insulin pens requires overcoming two major challenges: first, enhancing infusion accuracy; and second, enabling intervention alerts and efficacy analysis through data recording, storage, and interoperability.

In this regard, some enterprises are in the process of implementation, while others have already developed solutions, for example,Kailian Medical’s Newly Approved Smart Electric Insulin Pen — The New Generation Kailian Inno^®Pen.

Further Enhanced Infusion Precision: The New Generation of Kailian Yinuo^®A major highlight of the pen.

Specifically,New Generation Kailian Inno^®The pen’s infusion accuracy reaches 0.1 U, one-tenth that of traditional mechanical insulin pens. The product has a minimum infusion volume of 0.5 U, with increments set at 0.1 U; that is, the minimum single injection dose is 0.5 U, increasing thereafter in 0.1-U steps.

Improved infusion accuracy not only enhances the precision of diabetes management but also better meets the refined glycemic control needs of children and patients with brittle diabetes.

New Generation Kailian Inno^®The further enhancement of injection precision in the smart insulin pen also reflects Kailian Medical’s technical prowess in micro-infusion. In fact, micro-infusion has long been Kailian Medical’s core competency. With years of deep engagement in this field, the company has successfully developed two models of insulin pumps. “Transplanting the micro-infusion technology originally used in insulin pumps onto smart insulin pens represents, for Kailian Medical, a technological advantage akin to ‘dimensionality reduction attack’,” revealed Li Yin, co-founder of Kailian Medical, in an interview.

In addition to micro-infusion technology,To ensure precise dosing, the new-generation Kailian Yinuo^®The pen also employs electric injection technology and is equipped with automatic air purging and a countdown timer for needle withdrawal, addressing the aforementioned issue of dosage inaccuracy caused by missed air purging or premature needle removal, which can lead to insufficient or leaked liquid.

Moreover, the adoption of an electric infusion design stems from a subtle patient usage detail observed by Kailian Medical: the injection pain caused by uneven bolus delivery in traditional mechanical insulin pens. The precision motor employed in electric infusion enables smooth and steady delivery, thereby alleviating injection-related pain.

And in the new generation of Kailian Inno^®On the “body” of the pen, such design features that pay attention to the details of patient use are everywhere. For example, considering that some medications require refrigeration, the new generation Kailian Yinuo® pen has added an anti-condensation design; and considering the fear of injections among some adult patients and children, the new generation Kailian Yinuo^®The pen also features a hidden-needle design...

All these aspects demonstrate not only Kailian Medical’s technological prowess in addressing core pain points, but also its humanistic commitment to resolving them.

In addition to improving infusion accuracy, Kailian Medical is also committed to building an ecosystem based on its intelligent electric insulin pen—Kailian Inno.^®A Digital-Intelligent Management Ecosystem for Diabetes via Smart Pens.

To this end,Kailian Medical Launches an Intelligent MDI Therapy Plan for Diabetes. Specifically, the New Generation Kailian Inno^®The pen features built-in BLE Bluetooth technology, enabling fast and stable connectivity with smartphone apps and CGM/blood glucose meters. This facilitates data recording, storage, and interoperability, providing technical support for the implementation of various advanced functions.

Meanwhile, Kailian Medical has also developed a chronic disease data management platform for the hospital side (physician side) and the out-of-hospital Kailian Cloud for the patient side.^®APP software.Thus, based on Kailian Cloud^®Chronic Disease Data Management Platform: Physicians can promptly monitor patients’ medication adherence and adjust intervention plans in a timely manner, thereby gaining insights into the correlation between medication dosage and therapeutic outcomes; via out-of-hospital Kailian Cloud^®Through the app, patients can also view their injection records. If a dose is missed, the app will send injection reminders to improve patient adherence.

Moreover, Kailian Medical's Kailian Cloud^®The app also features a family-sharing function, allowing patients to share their data with family members so that they can understand the patient’s condition and provide support, thereby enhancing the patient’s confidence in treatment and adherence.

Thus, Kailian Medical’s intelligent MDI therapy plan for diabetes (integrated with CGM/blood glucose meters) not only covers the entire process of monitoring, intervention, follow-up, and intervention adjustment, but also connects multiple key stakeholders, including physicians, patients, and their families. It can rightly be described as a comprehensive solution for the refined, digital-intelligent management of diabetes.

This Complete Solution for Refined, Digital-Intelligent Diabetes Management (New Generation Kailian Yinuo^®pen) will officially go on sale in the near future. Sales channels cover all scenarios, both inside and outside hospitals, as well as online and offline. Kailian Medical also hopes to join hands with more industry partners to jointly promote the in-depth development of refined and digital-intelligent management of diabetes.

In the longer term, in addition to continuously developing innovative, refined, and digital-intelligent management products for chronic diseases, Kailian Medical will also launch its global expansion initiative and sincerely invites like-minded industry partners to join hands and move forward together!